Savara (SVRA) to Release Earnings on Monday

Key Points

• Savara (NASDAQ: SVRA) is set to announce its Q1 2025 earnings on August 11th, with analysts predicting a loss of ($0.12) per share.
• The company's stock price recently reached $2.68, with a market capitalization of approximately $462.34 million.
• Insider transactions include Director Richard J. Hawkins purchasing 48,225 shares at an average price of $2.04, increasing his holdings by 71.72%.

Savara (NASDAQ:SVRA - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Savara to post earnings of ($0.12) per share for the quarter.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). On average, analysts expect Savara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Stock Performance

Shares of SVRA traded up $0.01 on Friday, reaching $2.64. The company's stock had a trading volume of 433,988 shares, compared to its average volume of 894,571. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The stock has a market capitalization of $456.30 million, a P/E ratio of -5.50 and a beta of 0.40. The stock's 50 day simple moving average is $2.35 and its two-hundred day simple moving average is $2.66. Savara has a 12-month low of $1.89 and a 12-month high of $4.70.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SVRA. Wells Fargo & Company dropped their price objective on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. HC Wainwright downgraded shares of Savara from a "buy" rating to a "neutral" rating and lowered their price target for the company from $6.00 to $2.00 in a report on Thursday, May 29th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Finally, Guggenheim reaffirmed a "buy" rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $5.60.

Insiders Place Their Bets

In other news, Director Richard J. Hawkins purchased 48,225 shares of the stock in a transaction on Friday, June 20th. The shares were acquired at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the acquisition, the director directly owned 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.33% of the stock is owned by corporate insiders.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.